Covance Market Access - Asia-Pacific

Adam Gordois, Director, Health Economics BA (Hons), MSc Health Econ

Adam Gordois在澳大利亚和英国拥有超过18年的卫生经济咨询经验，跨越制药和医疗器械行业，政府和非营利组织。他的特殊专业领域包括市场准入和报销支持，医疗保健技术和政策评估，成本效益建模和预测。亚当已发表于各种卫生经济学和临床期刊的同行评审，从2006年到2015年，南威尔士州大学MMEDSC药物发展计划的药物经济课程。

Prior to joining Covance, Adam was Director of Health Economics and Social Policy at Deloitte Access Economics in Sydney following senior health economics roles at IMS (Australia), and a Research Fellow role at the York Health Economics Consortium, UK. Adam received an MSc in Health Economics (Distinction) from the University of York, and a BA in Business Economics (First Class Honours) from the University of Leicester.

Sam Colman, Director, HEOR, BEc, BSc (Hons), MBiostat

Sam Colman has over 18 years of experience as a statistician in government, academia, and industry, including 11 years in the pharmaceutical industry. He has expertise in several therapeutic areas including oncology, endocrine, neuroscience, cardiovascular disease and respiratory disease. Sam has designed and analysed a significant number of trial types including parallel randomised controlled trials, observational, cross-over, case-control, sample surveys, meta-analyses, and chart audits, and he has experience in all phases of clinical development (Phase I to Phase IV).

山姆有一个强有力的卫生经济学和结果research background with expertise in meta-analysis, indirect comparisons, and area-under-the-curve estimates and has worked on a number of successful PBAC submissions in Australia. Sam received a BEc and a BSc (Honours, Statistics) from the Australian National University and a Masters of Biostatistics from the University of Sydney.

Carol Lee，高级经理，BPHARM，DIP。医院Pharm。，Grad Cert Pharmaco经济学。

Carol’s expertise and interest includes assistance in the strategy development of reimbursement submissions of pharmaceuticals to the Australian and New Zealand Governments, feasibility studies of innovative medical devices and health outcomes.

在加入市场准入服务集团之前，Carol在詹森-Cilag和Sandoz（现在诺华）的监管和健康经济角色担任临床角色。Carol还在零售和医院药房工作的经验。卡罗尔接受了她的bpharm和dip。来自悉尼大学的医院药，蒙纳士大学药物经济学研究生证书。

Karen Schneider，Manager，BSC（Hons），MPH，PHD

Karen Schneider has over 8 years of experience in health economics for pharmaceutical and medical devices companies, academia, and other not-for-profit organisations. Karen’s area of special expertise is economic modelling, including cost-effectiveness, cost-utility, infectious disease and budget-impact modelling. Karen also specialises in market access strategy and the development of pharmaceutical reimbursement submissions to authorities including the PBAC in Australia and PHARMAC in New Zealand.

在2011年加入Covance之前，Karen举办了与艾滋病毒/艾滋病（NAPWA）的国家与艾滋病毒/艾滋病（NAPWA），社会大学（UNSW）和学校学校的艾滋病毒/艾滋病（Napwa）的研究作用。公共卫生和社区医学（SPHCM），UNSW。Karen于2013年被授予新南威尔士大学的博士学位。她的研究领域是艾滋病毒治疗和预防策略的成本效益。此外，Karen还获得悉尼大学公共卫生硕士学位，并从UNSW和Macquarie大学获得理学学士学位（荣誉）。

Dante Kemp, Manager, MSc Biostatistics

Dante Kemp has over 8 years of experience working in health economics and biostatistics. At Covance, Dante specialises in the development of economic models and the provision of statistical analyses. He manages health economics projects such as reimbursement submissions, evidence based literature reviews, retrospective and prospective collection of outcome and resource data, and pricing analyses. He also conducts statistical analyses including writing of statistical analysis plans, data management in SAS/STATA/Excel/VBA, development of statistical models, clinical trial design, and analysis of clinical trial data.

Prior to joining Covance in 2018, Dante worked as a statistician at John Wlodarczyk Consulting Services. His work there included planning and conducting the analysis of clinical trials, writing clinical study reports, developing global economic models, and supporting reimbursement submissions internationally. Dante’s was part of the first successful submission of a co-dependent technology in Australia, and his modelling approach was subsequently the standard in Australia. He has published on the association between cancer and immuno-suppression, and on the predictive factors and outcomes of bleeding complications following coronary intervention. Dante holds a Master’s of Science in Biostatistics from the New Jersey Institute of Technology, and a Bachelor’s of Science in Biochemistry from Rutger’s University.

OONO REDRON，BSC（HONS），MPH助理经理

Oona has several years’ experience in health economics within consulting, academic and industry sectors. Oona’s areas of expertise include critical appraisal of clinical trials, health economic audits of trial protocols, developing budget impact models, sourcing health outcomes and resource data, and undertaking literature reviews.

Prior to joining Covance, Oona worked at the Centre for Health Economics Research and Evaluation (CHERE) at the University of Technology Sydney (UTS) as a PBAC submission evaluator, working closely with both the ESC and PBAC Secretariats.

Oona also has experience in developing MSAC Assessment Reports, PICO confirmations and critiques. Oona’s technical understanding of medical devices and services stems from her background as a Medical Physicist based at Liverpool Hospital’s Cancer Therapy Centre and the PET and Nuclear Medicine Department, Royal Price Alfred Hospital. Oona has also gained extensive experience in regulatory affairs from working within the pharmaceutical industry including the development of complex regulatory strategies for drug reformulation and split dosing. She has registered many new medicines and devices with Australia’s TGA and New Zealand’s Medsafe.

Oona received a Master’s of Public Health (Health Economics Major with High Distinction) and a Bachelor of Science (Hons) in Applied Physics from UTS.